EAM
IMCR icon

Eagle Asset Management’s Immunocore IMCR Stock Holding History

Eagle Asset Management’s Portfolio IMCR Stock Details IMCR Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q3 		– Sell
-101,964
Closed -$3.71M – 562
2024
Q2 		$3.71M Buy
101,964
+58,866
+137% +$3M 0.02% 422
2024
Q1 		$2.71M Buy
+43,098
New +$2.96M 0.01% 449

Other funds holding IMCR

Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return
T. Rowe Price Investment Management
T. Rowe Price Investment Management Baltimore, Maryland $145B AUM 22.78% 1-Year Est. Return
RI
RTW Investments New York $10B AUM 135.35% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
Primecap Management
Primecap Management Pasadena, California $127B AUM 44.11% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return
BBA
Baker Bros. Advisors New York $17.4B AUM 131.5% 1-Year Est. Return
AC
Armistice Capital New York $5.62B AUM 36.06% 1-Year Est. Return
GA
General Atlantic New York $2.15B AUM 35.02% 1-Year Est. Return
BG
Bellevue Group Kuesnacht, Switzerland $4.2B AUM 54.85% 1-Year Est. Return

Eagle Asset Management's IMCR Position: Q3 2024 in Review

Eagle Asset Management sold out of Immunocore (IMCR) in Q3 2024, closing a stake of 101,964 shares — an estimated $3.71M sold.

Eagle Asset Management first reported a position in IMCR in Q1 2024 and held it in 2 quarters. The position peaked at $3.71M in Q2 2024. 130 funds tracked by Wall St. Rank hold IMCR as of Q3 2024.

  • Eagle Asset Management reported no remaining Immunocore position as of Q3 2024 after selling out during the quarter.
  • Eagle Asset Management sold 101,964 Immunocore shares in Q3 2024, an estimated $3.71M.
  • Eagle Asset Management first reported a position in Immunocore in Q1 2024 and held it in 2 quarters.
  • Eagle Asset Management's Immunocore position peaked at $3.71M in Q2 2024.
  • 130 funds tracked by Wall St. Rank held Immunocore as of Q3 2024.

Based on Eagle Asset Management's 13F filing for Q3 2024, filed 12 Nov 2024.